Axovant Gene Therapies Ltd. (AXGT) financial statements (2021 and earlier)

Company profile

Business Address 130 WEST 42ND STREET
NEW YORK, NY 10036
State of Incorp.
Fiscal Year End March 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
TTM
3/31/2020
3/31/2019
3/31/2018
3/31/2017
3/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments8981107154213276
Cash and cash equivalents8181107154213276
Short-term investments8     
Receivables222211
Other undisclosed current assets636265
Total current assets:9785115158220282
Noncurrent Assets
Operating lease, right-of-use asset12
Property, plant and equipment011300
Other noncurrent assets001   
Other undisclosed noncurrent assets 66 30
Total noncurrent assets:288330
TOTAL ASSETS:9994123161223282
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities9162236439
Accounts payable142491
Accrued liabilities8112132358
Debt 162110  
Due to related parties   132
Other undisclosed current liabilities0    5
Total current liabilities:93243474616
Noncurrent Liabilities
Long-term debt and lease obligation10234351 
Long-term debt, excluding current maturities  234351 
Operating lease, liability10
Other undisclosed noncurrent liabilities(1)     
Total noncurrent liabilities:10234351 
Total liabilities:103266909816
Stockholders' equity
Stockholders' equity attributable to parent89625671125267
Common stock0  000
Additional paid in capital876820741628460421
Accumulated other comprehensive income (loss)0(0)100 
Accumulated deficit(788)(759)(686)(557)(335)(154)
Total stockholders' equity:89625671125267
TOTAL LIABILITIES AND EQUITY:9994123161223282

Income statement (P&L) ($ in millions)

12/31/2020
TTM
3/31/2020
3/31/2019
3/31/2018
3/31/2017
3/31/2016
Operating expenses15(69)(127)(213)(180)(133)
Other undisclosed operating income (loss)4(3)(2)(7)(2) 
Operating income (loss):18(72)(129)(221)(182)(133)
Interest and debt expense1(4)(8)(8)(1) 
Income (loss) from continuing operations before equity method investments, income taxes:19(77)(136)(228)(183)(133)
Other undisclosed income from continuing operations before income taxes44881 
Income (loss) from continuing operations before income taxes:23(72)(129)(221)(182)(133)
Income tax expense (benefit)0(0)(0)(1)10
Net income (loss):23(73)(129)(222)(181)(133)
Other undisclosed net loss attributable to parent(5)     
Net income (loss) available to common stockholders, diluted:18(73)(129)(222)(181)(133)

Comprehensive Income ($ in millions)

12/31/2020
TTM
3/31/2020
3/31/2019
3/31/2018
3/31/2017
3/31/2016
Net income (loss):23(73)(129)(222)(181)(133)
Comprehensive income (loss):23(73)(129)(222)(181)(133)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(6)(1)1(0)0 
Comprehensive income (loss), net of tax, attributable to parent:17(74)(128)(222)(181)(133)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: